The stem cell therapy developer, exploiting research from Digital Photonics and Nanoscience Laboratory, has set up a US subsidiary.

TreeFrog Therapeutics, a France-based stem cell therapy developer advancing research from Digital Photonics and Nanoscience Laboratory (LP2N), completed a $75m series B round yesterday led by Bpifrance’s Large Venture fund.
Investment firm Leonard Green & Partners and XAnge, the venture capital arm of private equity group Siparex, also took part in the round, as did pharmaceutical firm Bristol Myers Squibb.
Founded in 2018, TreeFrog Therapeutics has created a high-throughput cell encapsulation technology dubbed C-Stem that enables the mass…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in